Related Experiment Video
Updated: Nov 29, 2025
09:18
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
8.6K
Surgical Adjuncts for Glioblastoma
Sara Hartnett1, Derek Kroll2, Michael A Vogelbaum2
1Department of Neurosurgery, USF Morsani School of Medicine, Tampa, FL, USA.
Neurosurgery Clinics of North America
|November 23, 2020
Summary
Directly delivering glioblastoma treatments during surgery bypasses the blood-brain barrier. This approach aims to effectively treat residual cancer cells, offering a promising strategy beyond traditional therapies.
Area of Science:
- Neuro-oncology
- Surgical Oncology
- Pharmacology
Background:
- Glioblastoma surgery offers survival benefits but is not curative.
- Systemic adjuvant therapies (radiation, chemotherapy) are limited by the blood-brain barrier.
- Limited efficacy of conventional treatments necessitates novel therapeutic strategies.
Purpose of the Study:
- To review direct intraoperative delivery methods for glioblastoma adjuvants.
- To summarize evaluated therapeutic agents and approaches.
- To identify remaining challenges in direct adjuvant delivery.
Main Methods:
- Literature review of studies on direct intraoperative adjuvant delivery for glioblastoma.
- Analysis of therapeutic agents and delivery techniques.
- Evaluation of clinical outcomes and challenges.
Main Results:
- Direct delivery bypasses the blood-brain barrier, enhancing drug penetration.
- Various agents and local delivery systems have been explored.
- Significant challenges remain in optimizing delivery and efficacy.
Conclusions:
- Intraoperative adjuvant delivery is a promising strategy for glioblastoma.
- Overcoming the blood-brain barrier is key to improving treatment outcomes.
- Further research is needed to refine techniques and overcome delivery challenges.
